GREENWICH, CT

Aptuit, Inc. announced today that it has secured additional funding to aid the company in its ongoing efforts to build an industry-leading drug development services organization. Temasek Holdings Limited joined Welsh, Carson, Anderson & Stowe (WCAS), Aptuit’s lead investor, with a minority investment, bringing potential capital available to more than $750 million. Aptuit also announced today the addition of John E. Nine, former Schering-Plough executive and current corporate advisor to Temasek, to its board of directors.

“We founded Aptuit with the goal of engineering a better drug development process and are well on our way to realizing our vision for the industry with three significant acquisitions under our belt,” noted Michael A. Griffith, CEO of Aptuit. “This latest investment from Temasek is a validation of our progress thus far and an endorsement for our future growth plans. We are working to add active pharmaceutical ingredient development and manufacturing capabilities and are seeking to make supplemental investments to deepen our current business lines, thus rounding out our service offering for customers.”

Mr. Griffith continued by saying, “Through this investment, we are also pleased to add John Nine to our board of directors. John’s experience working with top-tier pharmaceutical companies in the production and manufacturing of therapeutics is an invaluable addition to our already strong board of directors.”

Mr. Nine noted, “Aptuit’s vision and business model for a drug development services company are unique in the industry with a focus towards horizontal integrated management across all facets of the drug development continuum. The leadership at Aptuit has a strong history and track record of building similar, highly successful companies through acquisitions and investment. I look forward to working with the rest of the Board and management to contribute towards Aptuit’s global expansion plans.”

In addition to Michael A. Griffith and today’s appointment of John Nine, the Aptuit board of directors consists of three members from WCAS.

About Temasek Holdings

Temasek Holdings is an Asia investment company headquartered in Singapore. Established in 1974, it manages a diversified global portfolio of US $63 billion, spanning Singapore, Asia and the OECD economies. Its investments are in various industries including telecommunications and media, financial services, property, transportation and logistics, energy and resources, infrastructure, engineering and technology, as well as pharmaceuticals and biosciences. For more information, please visit http://www.temasekholdings.com.sg/.

About Welsh, Carson, Anderson & Stowe

Welsh, Carson, Anderson & Stowe (WCAS) is one of the largest private equity investment firms in the United States, and is the largest in the world focused exclusively on healthcare and information & business services. Since its founding in 1979, WCAS has organized 14 limited partnerships with total capital over $15 billion. Over that time, the company has invested in more than 135 companies and has funded over 650 follow-on acquisitions. For more information, please visit www.welshcarson.com.

About Aptuit

Aptuit, Inc. is an emerging company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators. The company was founded by a group of industry experts with extensive market experience who have a track record of building a similar, highly successful company through acquisitions and investment. Aptuit will provide a comprehensive suite of product development services and competencies to biotechnology companies and large, fully integrated pharmaceutical companies worldwide. Aptuit’s mission is to engineer a better drug development process, and is partnered with Welsh, Carson, Anderson & Stowe, one of the world’s largest private equity investors. For more information about Aptuit, please visit http://www.aptuit.com/.

Contact:

Michael A. Griffith, CEO, Aptuit, Inc. +1 203-422-6600, info@aptuit.com

or

Courtney E. Harris, Feinstein Kean Healthcare, +1 617-761-6744, courtney.harris@fkhealth.com